Prevalence of pretreatment HIV drug resistance in West African and Southeast Asian countries

• Main Authors: Nicole Ngo-Giang-Huong, Thu H.K. Huynh, Anoumou Y. Dagnra, Thomas D.Aquin Toni, Almoustapha I. Maiga, Dramane Kania, Sabrina Eymard-Duvernay, Martine Peeters, Cathia Soulie, Gilles Peytavin, Claire Rekacewicz, Marie Laure Chaix, Avelin F. Aghokeng
• Format: Journal
• Published: 2019
• Subjects: Medicine; Pharmacology, Toxicology and Pharmaceutics
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85060139226&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/63713
• Institution: Chiang Mai University

© The Author(s) 2018. Background ART in the developing world has moved to a new era with the WHO recommendation to test and immediately treat HIV-positive individuals. A high frequency of pretreatment HIV drug resistance (PDR) can compromise ART efficacy. Our study presents updated estimates of PDR in seven countries from West Africa (Burkina Faso, Cameroon, Côte d'Ivoire, Mali and Togo) and Southeast Asia (Thailand and Vietnam). Methods Eligible study participants were adult ART initiators, recruited from December 2015 to November 2016 in major ART clinics in each country. HIV drug resistance (HIVDR) tests were performed for all specimens and interpretation was done using the Stanford algorithm. Results Overall, 1153 participants were recruited and 1020 nt sequences were generated. PDR frequency among all initiators was 15.9% (95% CI: 13.8%-18.3%) overall, ranging from 9.6% and 10.2% in Burkina Faso and Thailand, respectively, 14.7% in Vietnam, 15.4% in Mali, 16.5% in Côte d'Ivoire and 19.3% in Cameroon, to 24.6% in Togo. The prevalence of NNRTI resistance mutations was 12%; NRTI and PI PDR prevalences were 4% and 3%, respectively. Conclusions Our study shows that in most countries PDR exceeded 10%, warranting the conduct of nationally representative surveys to confirm this trend. In the meantime, actions to prevent drug resistance, including transition from NNRTIs to more robust drug classes should be urgently implemented.